Nephros Company Top Insiders
| NEPH Stock | USD 5.41 0.55 11.32% |
Nephros employs about 31 people. The company is managed by 11 executives with a total tenure of roughly 17 years, averaging almost 1.0 years of service per executive, having 2.82 employees per reported executive. Assessment of Nephros' management performance can provide insight into the firm performance.
| Daron Evans CEO CEO and President Acting CFO, Director and Member of Audit Committee |
| Andrew Astor CEO CFO, CEO |
Nephros Management Team Effectiveness
The company has return on total asset (ROA) of 0.0764 % which means that it generated a profit of $0.0764 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1629 %, meaning that it created $0.1629 on every $100 dollars invested by stockholders. Nephros' management efficiency ratios could be used to measure how well Nephros manages its routine affairs as well as how well it operates its assets and liabilities.The market capitalization of Nephros is $51.65 Million. 30% of Nephros outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please take into account that even companies with profitable outlook can generate negative future returns on their equity. If the true value of the firm is less than the current market value, you may not be able generate positive returns on investment in the long run.
Some institutional investors establish a significant position in stocks such as Nephros in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Nephros, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Nephros Workforce Comparison
Nephros is considered to be number one stock in number of employees category among its peers. The total workforce of Consumer Discretionary industry is now estimated at about 514. Nephros holds roughly 31.0 in number of employees claiming about 6% of stocks in Consumer Discretionary industry.
The company has Profit Margin (PM) of 0.08 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.07 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.07. Nephros Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nephros insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nephros' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Nephros insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Daron Evans over two months ago Acquisition by Daron Evans of 1111 shares of Nephros at 2.7 subject to Rule 16b-3 | ||
Andrew Astor over three months ago Acquisition by Andrew Astor of 2500 shares of Nephros at 7.6687 subject to Rule 16b-3 | ||
Spandow Oliver J. over three months ago Acquisition by Spandow Oliver J. of 3666 shares of Nephros subject to Rule 16b-3 | ||
Persen Malcolm C over six months ago Acquisition by Persen Malcolm C of 5921 shares of Nephros subject to Rule 16b-3 | ||
Krandel Judy over six months ago Acquisition by Krandel Judy of 54359 shares of Nephros at 1.68 subject to Rule 16b-3 | ||
Gwydir Tom over six months ago Acquisition by Gwydir Tom of 27613 shares of Nephros subject to Rule 16b-3 | ||
Andrew Astor over six months ago Acquisition by Andrew Astor of 1000 shares of Nephros at 6.96 subject to Rule 16b-3 | ||
Spandow Oliver J. over a year ago Acquisition by Spandow Oliver J. of 7050 shares of Nephros at 1.47 subject to Rule 16b-3 |
Nephros Notable Stakeholders
A Nephros stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Nephros often face trade-offs trying to please all of them. Nephros' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Nephros' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Daron Evans | CEO and President Acting CFO, Director and Member of Audit Committee | Profile | |
| Andrew Astor | CFO, CEO | Profile | |
| Robert Banks | CEO President | Profile | |
| Greg Lucas | President Systems | Profile | |
| Alfred Vargas | Director Operations | Profile | |
| Vashone Thomas | Regulatory, Quality | Profile | |
| Joleen Turner | VP Devel | Profile | |
| Judy CFA | Chief Officer | Profile | |
| Judy Mazzini | Controller | Profile | |
| MS MBA | Inc Products | Profile | |
| Brianne McGuire | Marketing Brand | Profile |
About Nephros Management Performance
The success or failure of an entity such as Nephros often depends on how effective the management is. Nephros management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Nephros management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Nephros management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey. Nephros operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 34 people.
Nephros Workforce Analysis
Traditionally, organizations such as Nephros use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Nephros within its industry.Nephros Manpower Efficiency
Return on Nephros Manpower
| Revenue Per Employee | 456.8K | |
| Revenue Per Executive | 1.3M | |
| Net Income Per Employee | 2.4K | |
| Net Income Per Executive | 6.7K | |
| Working Capital Per Employee | 217.3K | |
| Working Capital Per Executive | 612.4K |
Complementary Tools for Nephros Stock analysis
When running Nephros' price analysis, check to measure Nephros' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nephros is operating at the current time. Most of Nephros' value examination focuses on studying past and present price action to predict the probability of Nephros' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nephros' price. Additionally, you may evaluate how the addition of Nephros to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |